Home » Stocks » RIGL

Rigel Pharmaceuticals, Inc. (RIGL)

Stock Price: $3.84 USD 0.26 (7.26%)
Updated Mar 5, 2021 4:00 PM EST - Market closed
Market Cap 652.96M
Revenue (ttm) 108.62M
Net Income (ttm) -29.74M
Shares Out 168.75M
EPS (ttm) -0.18
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day March 5
Last Price $3.84
Previous Close $3.58
Change ($) 0.26
Change (%) 7.26%
Day's Open 3.63
Day's Range 3.20 - 3.85
Day's Volume 5,788,625
52-Week Range 1.23 - 5.50

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Zacks Investment Research - 5 days ago

Rigel (RIGL) delivered earnings and revenue surprises of -10.00% and 0.44%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

PRNewsWire - 5 days ago

SOUTH SAN FRANCISCO, Calif., March 2, 2021 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today reported financial results for the fourth quarter and full year ended December 31, 2...

PRNewsWire - 1 week ago

SOUTH SAN FRANCISCO, Calif., Feb. 23, 2021 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that it will report its fourth quarter and year end 2020 financial results ...

The Motley Fool - 2 weeks ago

Here's why this stock's big run-up in recent months could be just the beginning.

InvestorPlace - 2 weeks ago

A newly announced deal between Rigel Pharmaceuticals and sector behemoth Eli Lilly has RIGL stock climbing in trading today. The post RIGL Stock: Why Rigel Pharmaceuticals Is Climbing Today ap...

Zacks Investment Research - 2 weeks ago

Rigel (RIGL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

The Motley Fool - 2 weeks ago

The company is teaming up with Eli Lilly on the development of a promising immune disease drug.

PRNewsWire - 2 weeks ago

INDIANAPOLIS and SOUTH SAN FRANCISCO, Calif., Feb. 18, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced a global exclusive ...

Other stocks mentioned: LLY
PRNewsWire - 1 month ago

SOUTH SAN FRANCISCO, Calif., Jan. 29, 2021 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced it has been awarded $16.5 million by the U.S. Department of Defense's (DOD...

Seeking Alpha - 1 month ago

Rigel's value proposition revolves solely around growing sales of its already approved Tavalisse for ITP in the US and worldwide and getting the label extended to include wAIHA. Tavalisse sale...

PRNewsWire - 1 month ago

SOUTH SAN FRANCISCO, Calif., Jan. 11, 2021 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today provided a business update, including preliminary total revenue, TAVALISSE® (fostama...

PRNewsWire - 2 months ago

SOUTH SAN FRANCISCO, Calif., Jan. 7, 2021 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Raul Rodriguez, the company's president and chief executive officer, i...

Zacks Investment Research - 2 months ago

Investors need to pay close attention to Rigel Pharmaceuticals (RIGL) stock based on the movements in the options market lately.

Seeking Alpha - 3 months ago

Rigel's approved drug Tavalisse can be useful to cITP patients in a third line setting, but the market isn't huge. Current lead indication WIHA is not large either, and the same safety issues ...

PRNewsWire - 3 months ago

SOUTH SAN FRANCISCO, Calif., Dec. 4, 2020 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that data related to TAVALISSE® (fostamatinib disodium hexahydrate) tablets...

PRNewsWire - 3 months ago

SOUTH SAN FRANCISCO, Calif. and PETACH TIKVA, Israel, Nov. 23, 2020 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) and Medison Pharma (Medison) today announced that Health Canada h...

PRNewsWire - 3 months ago

SOUTH SAN FRANCISCO, Calif., Nov. 17, 2020 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it has reached agreement with the U.S. Food and Drug Administration (...

PRNewsWire - 3 months ago

SOUTH SAN FRANCISCO, Calif., Nov. 10, 2020 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Raul Rodriguez, the company's president and chief executive officer, ...

Seeking Alpha - 4 months ago

Rigel Pharmaceuticals' (RIGL) CEO Raul Rodriguez on Q3 2020 Results - Earnings Call Transcript

Zacks Investment Research - 4 months ago

Rigel (RIGL) delivered earnings and revenue surprises of 33.33% and 4.51%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

PRNewsWire - 4 months ago

SOUTH SAN FRANCISCO, Calif., Oct. 9, 2020 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced enrollment of the first patients in a multicenter, Phase 2 trial to evaluat...

Zacks Investment Research - 5 months ago

Rigel Pharmaceuticals (RIGL) is developing its thrombocytopenia drug, Tavalisse, as a potential treatment for hospitalized COVID-19 patients.

24/7 Wall Street - 5 months ago

Rigel Pharmaceuticals Inc. (NASDAQ: RIGL) has announced that it will push forward with a midstage trial in the treatment of COVID-19.

Market Watch - 5 months ago

Shares of Rigel Pharmaceuticals Inc. RIGL, +1.21% were up 10.4% in premarket trading on Thursday after the company said it had started a randomized, double-blind, placebo-controlled Phase 2 cl...

PRNewsWire - 5 months ago

SOUTH SAN FRANCISCO, Calif., Sept. 17, 2020 /PRNewswire/ -- Rigel Pharmaceuticals, Inc.

Seeking Alpha - 5 months ago

Rigel has an already established asset and is expecting results from another Phase 3 trial.

Seeking Alpha - 5 months ago

Rigel Is Once Again At A Bargain Price After A Temporary COVID-19 Rally

PRNewsWire - 5 months ago

SOUTH SAN FRANCISCO, Calif., Sept. 9, 2020 /PRNewswire/ -- Rigel Pharmaceuticals (Nasdaq: RIGL) today announced that Dean Schorno, the company's chief financial officer, is scheduled to presen...

PRNewsWire - 6 months ago

SOUTH SAN FRANCISCO, Calif., Sept. 2, 2020 /PRNewswire/ -- Rigel Pharmaceuticals (Nasdaq: RIGL) today announced that Raul Rodriguez, the company's president and chief executive officer, is sch...

PRNewsWire - 6 months ago

SOUTH SAN FRANCISCO, Calif., Aug. 21, 2020 /PRNewswire/ -- Rigel Pharmaceuticals (Nasdaq: RIGL) today announced that it has granted awards pursuant to the Rigel Pharmaceuticals, Inc.

Seeking Alpha - 7 months ago

Rigel Pharmaceuticals, Inc. (RIGL) CEO Raul Rodriguez on Q2 2020 Results - Earnings Call Transcript

Zacks Investment Research - 7 months ago

Rigel (RIGL) delivered earnings and revenue surprises of 23.08% and 12.23%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research - 7 months ago

Rigel (RIGL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

PRNewsWire - 7 months ago

SOUTH SAN FRANCISCO, Calif., July 28, 2020 /PRNewswire/ -- Rigel Pharmaceuticals, Inc.

Benzinga - 7 months ago

Rigel Pharmaceuticals (NASDAQ: RIGL) shares are trading higher on Monday after the company announced the publication of post-hoc data analysis of TAVALISSE in the British Journal of Haematology.

PRNewsWire - 7 months ago

SOUTH SAN FRANCISCO, Calif., July 27, 2020 /PRNewswire/ -- Rigel Pharmaceuticals, Inc.

Seeking Alpha - 7 months ago

Rigel: Fostamatinib Joins The COVID-19 Campaign And Resuscitates My Bullish Outlook

The Motley Fool - 7 months ago

The biotechnology company is hoping to improve coronavirus care.

Market Watch - 7 months ago

Shares of Rigel Pharmaceuticals Inc. RIGL, +21.34% gained 25% in premarket trading on Tuesday after announcing that a drug used to treat an autoimmune disorder will be tested in a clinical tri...

PRNewsWire - 7 months ago

SOUTH SAN FRANCISCO, Calif., July 14, 2020 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced the initiation of an investigator-sponsored trial (IST) being conducted by...

Zacks Investment Research - 8 months ago

Rigel Pharmaceuticals (RIGL) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.

PRNewsWire - 8 months ago

SOUTH SAN FRANCISCO, Calif., June 17, 2020 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Dean Schorno, the company's chief financial officer, is scheduled to ...

PRNewsWire - 8 months ago

SOUTH SAN FRANCISCO, Calif., June 11, 2020 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that data related to TAVALISSE® (fostamatinib disodium hexahydrate) tablet...

PRNewsWire - 9 months ago

SOUTH SAN FRANCISCO, Calif., June 3, 2020 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that data related to R835, the company's investigational IRAK1/4 inhibitor,...

PRNewsWire - 9 months ago

SOUTH SAN FRANCISCO, Calif., May 26, 2020 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Raul Rodriguez, the company's president and chief executive officer, i...

Seeking Alpha - 9 months ago

Rigel Pharmaceuticals Remains Undervalued Despite Slowdown In Q1 Tavalisse Sales

Seeking Alpha - 10 months ago

Rigel Pharmaceuticals, Inc. (RIGL) CEO Raul Rodriguez on Q1 2020 Results - Earnings Call Transcript

Zacks Investment Research - 10 months ago

Rigel (RIGL) delivered earnings and revenue surprises of 0.00% and -2.08%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research - 10 months ago

Rigel (RIGL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

The Motley Fool - 11 months ago

Success in clinical trials doesn't guarantee success on the market.

Other stocks mentioned: AERI, AXSM, BIIB, BLUE, PBYI, PFE

About RIGL

Rigel Pharmaceuticals, Inc., a biotechnology company, engages in the discovery and development of small molecule drugs for the treatment of immune and hematologic disorders, cancer, and rare diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is in phase III clinical trials for warm autoimmune hemolytic anemia; R835, an oral interleukin receptor associated kinase 1/4 inhibitor, which is in phase I clinical tr... [Read more...]

Industry
Biotechnology
IPO Date
Nov 29, 2000
CEO
Raul Rodriguez
Country
United States
Stock Exchange
NASDAQ
Ticker Symbol
RIGL
Full Company Profile

Financial Performance

In 2020, RIGL's revenue was $108.62 million, an increase of 83.21% compared to the previous year's $59.29 million. Losses were -$29.74 million, -55.54% less than in 2019.

Financial Statements

Analyst Forecasts

According to 7 analysts, the average rating for RIGL stock is "Buy." The 12-month stock price forecast is 8.50, which is an increase of 121.35% from the latest price.

Price Target
$8.50
(121.35% upside)
Analyst Consensus: Buy